Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 28;14(1):31433.
doi: 10.1038/s41598-024-83085-0.

The mediating role of primary sclerosing cholangitis in the association between ulcerative colitis and hepatobiliary cancer investigated through Mendelian randomization

Affiliations

The mediating role of primary sclerosing cholangitis in the association between ulcerative colitis and hepatobiliary cancer investigated through Mendelian randomization

Fangming Wang et al. Sci Rep. .

Abstract

This study explored the causal relationships among primary sclerosing cholangitis (PSC), ulcerative colitis (UC), and hepatobiliary cancer (HBC) by using bidirectional two-sample, two-step Mendelian randomization (MR) analysis. Genetic variants associated with PSC and UC from the FinnGen research database were used for instrumental variable-based analyses. Mediation analyses were conducted to examine the role of PSC and UC in HBC risk. The findings revealed a causal effect of genetic predisposition to UC on PSC risk (inverse-variance-weighted [IVW] analysis odds ratio [OR] 1.145, p < 0.001), whereas no reverse causality was observed. Although UC showed no direct causal effect on HBC risk, genetic susceptibility to PSC significantly increased the risk of HBC (IVW analysis OR = 1.855, p < 0.001). Mediation analysis further identified PSC as a significant mediator amplifying the causal effect of UC on HBC risk (effect size = 0.083). These results established a causal link between genetic susceptibility to UC and increased risk of PSC, and highlighted the critical role of PSC in mediating the impact of UC on HBC risk.

Keywords: Mendelian randomization; causal relationship; hepatobiliary cancer; mediator; primary sclerosing cholangitis; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
This Figure illustrates a diagram of the MR study. The study’s flowchart is structured upon three core assumptions. (I) Relevance to Exposure: The instrumental variables (IVs) must exhibit a statistically significant connection to the exposure under investigation (II) Independence from Confounding: The IVs should remain disconnected from any recognized confounding factors that could potentially modify the relationship between an exposure and its associated outcome. (III) Exclusion Restriction: The IVs should bear no direct influence on the outcomes; their impact is solely mediated by their effects on the exposure of interest.
Fig. 2
Fig. 2
MR estimates derived from the fixed-effect IVW method, MR-Egger regression, weighted median method, weighted-mode method, simple-mode and random-effect IVW method to assess the causal effect between PSC and UC. (A) Results of forward MR and reverse MR analysis between PSC and UC. (B) Scatter plots showing the MR effect of each exposure on PSC. (C) Scatter plots showing the MR effect of each exposure on UC. PSC primary sclerosing cholangitis, UC ulcerative colitis.
Fig. 3
Fig. 3
MR estimates derived from the fixed-effect IVW method, MR-Egger regression, weighted median method, weighted-mode method, simple-mode and random-effect IVW method to assess the causal effect of UC on HBC and PSC on HBC. (A) Results of MR analysis between liability to UC or PSC and the HBC risk. (B) Scatter plots showing the MR effect of each exposure on PSC. (C) Scatter plots showing the MR effect of each exposure on UC. UC ulcerative colitis, PSC primary sclerosing cholangitis, HBC hepatobiliary cancer.

Similar articles

References

    1. Yang, Y. et al. Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges. Cancer Commun.40 (2020). - PMC - PubMed
    1. van Munster, K. N., Dijkgraaf, M. G. W., Elferink, O., Beuers, R. P. J., Ponsioen, C. Y. & U. & Symptom patterns in the daily life of PSC patients. Liver Int.42, 1562–1570. 10.1111/liv.15271 (2022). - PMC - PubMed
    1. Kasztelan-Szczerbinska, B., Rycyk-Bojarzynska, A., Szczerbinska, A. & Cichoz-Lach, H. Selected aspects of the intricate background of immune-related cholangiopathies: A critical overview. Nutrients10.3390/nu15030760 (2023). - PMC - PubMed
    1. Trivedi, P. J. & Hirschfield, G. M. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut70, 1989–2003. 10.1136/gutjnl-2020-322362 (2021). - PubMed
    1. Bowlus, C. L., Lim, J. K. & Lindor, K. D. AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: Expert review. Clin. Gastroenterol. Hepatol.17, 2416–2422. 10.1016/j.cgh.2019.07.011 (2019). - PubMed

MeSH terms

LinkOut - more resources